Company intelligence / Profile preview
Intrepida Bio, Inc.
San Diego, California, United Statesintrepidabio.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
As of 2025, Intrepida Bio has one drug (IB-003) in Phase 1 clinical trials, one drug (IB-001) in preclinical development targeting BAG3 for pancreatic cancer, and one discontinued program (IB-002). The company's anti-BAG3 antibodies have shown promise in preclinical studies by slowing tumor growth, reducing metastases, and boosting survival in both in-vitro and animal studies.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesSmall molecule drugs
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Biouniversa s.r.l.
Beyond the preview
Go deeper on Intrepida Bio, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intrepida Bio, Inc..